← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Arvinas, Inc. (ARVN) 10-Year Financial Performance & Capital Metrics

ARVN • • Industrial / General
HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology
AboutArvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.Show more
  • Revenue $263M +235.5%
  • EBITDA -$244M +38.3%
  • Net Income -$199M +45.8%
  • EPS (Diluted) -2.77 +58.2%
  • Gross Margin 100%
  • EBITDA Margin -92.48% +81.6%
  • Operating Margin -94.99% +81.4%
  • Net Margin -75.51% +83.9%
  • ROE -32.56% +45.7%
  • ROIC -45.63% +36.3%
  • Debt/Equity 0.02 +256.2%
  • Interest Coverage -
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 84 (top 16%)
  • ✓High quality earnings: Operating CF exceeds net income
  • ✓Strong 5Y sales CAGR of 43.7%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 2/9
  • ✗Negative free cash flow
  • ✗Shares diluted 29.5% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y43.71%
3Y70.01%
TTM93.85%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM81.04%

EPS CAGR

10Y-
5Y-
3Y-
TTM82.66%

ROCE

10Y Avg-35.45%
5Y Avg-26.73%
3Y Avg-29.63%
Latest-26.21%

Peer Comparison

Solid Tumor Oncology
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
TLXTelix Pharmaceuticals Limited2.49B7.4353.0755.85%3.98%15.63%0.36%1.02
EXELExelixis, Inc.12.18B45.4425.8218.49%29.63%31.37%5.2%0.09
BBOTBridgeBio Oncology Therapeutics Inc.919.87M11.5025-25.73%
INBXInhibrx Biosciences, Inc.1.04B71.800.62-88.89%-110.78%-421.09%0.06
NUVBNuvation Bio Inc.2.1B6.14-2.91-8.13%-66.74%0.02
RLAYRelay Therapeutics, Inc.1.32B7.63-3.23-60.83%-26.71%-48.97%0.06
ORICORIC Pharmaceuticals, Inc.1.12B11.52-6.30-33.24%0.01
ZLABZai Lab Limited2.09B18.82-7.2449.59%-46.83%-27.21%0.18

Profit & Loss

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+6.67M7.58M14.32M42.98M25.9M53.6M131.4M78.5M263.4M
Revenue Growth %-0.14%0.89%2%-0.4%1.07%1.45%-0.4%2.36%
Cost of Goods Sold+000000000
COGS % of Revenue---------
Gross Profit+6.67M7.58M14.32M42.98M25.9M53.6M131.4M78.5M263.4M
Gross Margin %1%1%1%1%1%1%1%1%1%
Gross Profit Growth %-0.14%0.89%2%-0.4%1.07%1.45%-0.4%2.36%
Operating Expenses+23.14M32.34M58.13M94.5M146.7M242M394.6M480M513.6M
OpEx % of Revenue3.47%4.27%4.06%2.2%5.66%4.51%3%6.11%1.95%
Selling, General & Admin3.2M3.55M12.93M27.31M38.3M61.6M79.6M100.3M165.4M
SG&A % of Revenue0.48%0.47%0.9%0.64%1.48%1.15%0.61%1.28%0.63%
Research & Development19.94M28.79M45.19M67.19M108.4M180.4M315M379.7M348.2M
R&D % of Revenue2.99%3.8%3.16%1.56%4.19%3.37%2.4%4.84%1.32%
Other Operating Expenses00102.73K000000
Operating Income+-16.47M-24.76M-43.8M-51.52M-120.8M-188.4M-263.2M-401.5M-250.2M
Operating Margin %-2.47%-3.27%-3.06%-1.2%-4.66%-3.51%-2%-5.11%-0.95%
Operating Income Growth %--0.5%-0.77%-0.18%-1.34%-0.56%-0.4%-0.53%0.38%
EBITDA+-16.03M-24.41M-43.1M-49.27M-117.6M-182.4M-255M-394.8M-243.6M
EBITDA Margin %-2.4%-3.22%-3.01%-1.15%-4.54%-3.4%-1.94%-5.03%-0.92%
EBITDA Growth %--0.52%-0.77%-0.14%-1.39%-0.55%-0.4%-0.55%0.38%
D&A (Non-Cash Add-back)436.33K347.39K706K2.25M3.2M6M8.2M6.7M6.6M
EBIT-14.37M-24M-41.42M-70.21M-120.8M-188.4M-263.2M-401.5M-250.2M
Net Interest Income+360.37K151.03K2.41M4.5M3.52M1.7M12M38.8M54.8M
Interest Income427.77K201.39K2.47M4.6M3.59M1.8M12M38.8M54.8M
Interest Expense67.4K50.36K57.44K100K65K100K000
Other Income/Expense2.03M711.06K2.32M-18.79M1.5M-2.6M1.6M35.1M51.9M
Pretax Income+-14.44M-24.05M-41.48M-70.3M-119.3M-191M-261.6M-366.4M-198.3M
Pretax Margin %-2.16%-3.17%-2.9%-1.64%-4.61%-3.56%-1.99%-4.67%-0.75%
Income Tax+-87.41K0000020.9M900K600K
Effective Tax Rate %0.99%1%1%1%1%1%1.08%1%1%
Net Income+-14.35M-24.05M-41.48M-70.29M-119.3M-191M-282.5M-367.3M-198.9M
Net Margin %-2.15%-3.17%-2.9%-1.64%-4.61%-3.56%-2.15%-4.68%-0.76%
Net Income Growth %--0.68%-0.72%-0.69%-0.7%-0.6%-0.48%-0.3%0.46%
Net Income (Continuing)-14.35M-24.05M-41.48M-70.3M-119.3M-191M-282.5M-367.3M-198.9M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)+-7.56-1.38-1.31-1.89-3.02-3.82-5.31-6.62-2.77
EPS Growth %-0.82%0.05%-0.44%-0.6%-0.26%-0.39%-0.25%0.58%
EPS (Basic)-7.56-1.38-1.31-1.89-3.02-3.82-5.31-6.62-2.77
Diluted Shares Outstanding1.9M20.73M31.63M32.93M39.53M50M53.2M55.5M71.9M
Basic Shares Outstanding1.9M20.73M31.63M32.93M39.53M50M53.2M55.5M71.9M
Dividend Payout Ratio---------

Balance Sheet

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+37.28M65.53M195.68M290.88M703.1M1.55B1.24B1.28B1.07B
Cash & Short-Term Investments35.56M39.17M187.83M280.87M688.6M1.5B1.21B1.26B1.04B
Cash Only5.09M30.91M3.19M9.21M588.4M108.3M81.3M311.7M100.5M
Short-Term Investments30.47M8.26M184.64M271.66M100.2M1.39B1.12B949.3M938.9M
Accounts Receivable1.41M26.04M5.03M6.28M8.4M25.7M8M7.2M13.7M
Days Sales Outstanding77.181.25K128.2253.34118.38175.0122.2233.4818.98
Inventory000000000
Days Inventory Outstanding---------
Other Current Assets000004.5M26.9M12M14.2M
Total Non-Current Assets+654.61K1.32M3.6M10.76M14.3M29.1M28.6M24.4M24.1M
Property, Plant & Equipment633.85K1.3M3.58M10.73M14.3M16.6M17.8M14M16M
Fixed Asset Turnover10.52x5.83x4.00x4.00x1.81x3.23x7.38x5.61x16.46x
Goodwill000000000
Intangible Assets000000000
Long-Term Investments000000000
Other Non-Current Assets20.76K20.76K20.76K26.76K012.5M10.8M10.4M8.1M
Total Assets+37.94M66.85M199.28M301.64M717.4M1.58B1.27B1.3B1.09B
Asset Turnover0.18x0.11x0.07x0.14x0.04x0.03x0.10x0.06x0.24x
Asset Growth %-0.76%1.98%0.51%1.38%1.2%-0.2%0.03%-0.16%
Total Current Liabilities+10.03M17.85M22.98M32.81M49.2M261.7M295.1M257.1M229.8M
Accounts Payable1.57M596.53K2.76M4.56M7.1M31.3M5.7M17.8M13.4M
Days Payables Outstanding---------
Short-Term Debt141.21K159.26K154.46K000000
Deferred Revenue (Current)1000K1000K1000K1000K1000K1000K1000K1000K1000K
Other Current Liabilities0005.81M9M12.4M18.7M48M0
Current Ratio3.72x3.67x8.52x8.86x14.29x5.93x4.20x4.98x4.64x
Quick Ratio3.72x3.67x8.52x8.86x14.29x5.93x4.20x4.98x4.64x
Cash Conversion Cycle---------
Total Non-Current Liabilities+3.87M48.75M39.63M42.14M26M538.2M408.8M387.5M299.9M
Long-Term Debt312.57K151.12K2M2M2M1M1M800K600K
Capital Lease Obligations0001.71M1.1M2.9M2.7M500K7.3M
Deferred Tax Liabilities-56.85M-61.43M0000000
Other Non-Current Liabilities56.76K50.89K150K000000
Total Liabilities13.91M66.6M62.61M74.96M75.2M799.9M703.9M644.6M529.7M
Total Debt+453.79K310.39K2.15M4.39M4.1M5M5.5M3.2M9.7M
Net Debt-4.63M-30.6M-1.04M-4.82M-584.3M-103.3M-75.8M-308.5M-90.8M
Debt / Equity0.02x1.26x0.02x0.02x0.01x0.01x0.01x0.00x0.02x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage-244.34x-491.69x-762.57x-515.25x-1858.46x-1884.00x---
Total Equity+24.03M245.87K136.67M226.69M642.2M781.7M564.9M660M561.7M
Equity Growth %--0.99%554.85%0.66%1.83%0.22%-0.28%0.17%-0.15%
Book Value per Share12.660.014.326.8816.2415.6310.6211.897.81
Total Shareholders' Equity24.03M245.87K136.67M226.69M642.2M781.7M564.9M660M561.7M
Common Stock947.54K1.19M31.24K38.46K00100K100K100K
Retained Earnings-33.8M-62.42M-302.26M-372.56M-491.9M-682.9M-965.4M-1.33B-1.53B
Treasury Stock000000000
Accumulated OCI-28.68K-9.75K-217.72K107.58K600K-4.6M-19.2M-3.1M1M
Minority Interest000000000

Cash Flow

Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-19.4M5.11M-16.12M-40.63M-89.76M559.4M-273.5M-347.8M-259.3M
Operating CF Margin %-2.91%0.67%-1.13%-0.95%-3.47%10.44%-2.08%-4.43%-0.98%
Operating CF Growth %-1.26%-4.15%-1.52%-1.21%7.23%-1.49%-0.27%0.25%
Net Income-14.35M-24.05M-41.48M-70.29M-119.33M-191M-282.5M-367.3M-198.9M
Depreciation & Amortization436.33K347.39K706K2.25M4.02M6M8.2M6.7M6.6M
Stock-Based Compensation525.59K245.05K11.63M20.07M30.2M57.1M75.5M71.6M88.2M
Deferred Taxes-1.01M-5.87K193.78K0-395.07K0000
Other Non-Cash Items556.42K362.07K266.03K169.17K1.69M9M7.9M-14.4M-14.6M
Working Capital Changes-5.56M28.21M12.57M7.17M-5.94M678.3M-82.6M-44.4M-140.6M
Change in Receivables-578.93K-25M22.22M2.78M-1M-30.2M14M800K-5.7M
Change in Inventory02.26M-3.26M-2.07M6.34M0000
Change in Payables1.2M-969.48K2M1.61M2.04M27.9M20.2M17.3M-21.2M
Cash from Investing+-20.11M20.87M-179.67M-93.1M164.25M-1.31B242.8M203.5M34.7M
Capital Expenditures-306.67K-1.01M-2.83M-6.24M-6.45M-4.7M-6.8M-2.9M-1.8M
CapEx % of Revenue0.05%0.13%0.2%0.15%0.25%0.09%0.05%0.04%0.01%
Acquisitions---------
Investments---------
Other Investing-50K21.88M-176.83M-86.8M395.07M0-400K00
Cash from Financing+-149.74K-161.36K168.06M139.74M504.67M278.6M4.7M374.7M7.9M
Debt Issued (Net)---------
Equity Issued (Net)---------
Dividends Paid000000000
Share Repurchases---------
Other Financing00-3.35M0-20.93M14M000
Net Change in Cash---------
Free Cash Flow+-19.71M4.1M-18.95M-46.87M-96.2M554.7M-280.3M-350.7M-261.1M
FCF Margin %-2.96%0.54%-1.32%-1.09%-3.71%10.35%-2.13%-4.47%-0.99%
FCF Growth %-1.21%-5.62%-1.47%-1.05%6.77%-1.51%-0.25%0.26%
FCF per Share-10.390.20-0.60-1.42-2.4311.09-5.27-6.32-3.63
FCF Conversion (FCF/Net Income)1.35x-0.21x0.39x0.58x0.75x-2.93x0.97x0.95x1.30x
Interest Paid00000100K000
Taxes Paid00000011.1M11.1M2.3M

Key Ratios

Metric201620172018201920202021202220232024
Return on Equity (ROE)-59.72%-198.12%-60.59%-38.69%-27.46%-26.83%-41.96%-59.97%-32.56%
Return on Invested Capital (ROIC)-63.68%--62.41%-21.62%-64.77%-38.38%-33.82%-71.65%-45.63%
Gross Margin100%100%100%100%100%100%100%100%100%
Net Margin-215.18%-317.32%-289.59%-163.56%-460.62%-356.34%-214.99%-467.9%-75.51%
Debt / Equity0.02x1.26x0.02x0.02x0.01x0.01x0.01x0.00x0.02x
Interest Coverage-244.34x-491.69x-762.57x-515.25x-1858.46x-1884.00x---
FCF Conversion1.35x-0.21x0.39x0.58x0.75x-2.93x0.97x0.95x1.30x
Revenue Growth-13.64%89%200.03%-39.73%106.95%145.15%-40.26%235.54%

Revenue by Segment

2024
License130M
License Growth-

Frequently Asked Questions

Growth & Financials

Arvinas, Inc. (ARVN) reported $312.3M in revenue for fiscal year 2024. This represents a 4583% increase from $6.7M in 2016.

Arvinas, Inc. (ARVN) grew revenue by 235.5% over the past year. This is strong growth.

Arvinas, Inc. (ARVN) reported a net loss of $58.5M for fiscal year 2024.

Dividend & Returns

Arvinas, Inc. (ARVN) has a return on equity (ROE) of -32.6%. Negative ROE indicates the company is unprofitable.

Arvinas, Inc. (ARVN) had negative free cash flow of $329.5M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.